Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association

Journal of Clinical Lipidology

Volumn 7, Issue 4, 2013, Pages 304-383

  Bays, Harold E ^a   Toth, Peter P ^b,k   Kris Etherton, Penny M ^c   Abate, Nicola ^d   Aronne, Louis J ^e   Brown, W Virgil ^f   Gonzalez Campoy, J Michael ^g   Jones, Steven R ^h   Kumar, Rekha ^e   La Forge, Ralph ⁱ   Samuel, Varman T ^j,l  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b CGH MEDICAL CENTER   (United States)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^e Department of Obstetrics Gynecology   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Minnesota Center for Obesity Metabolism and Endocrinology   (United States)

^h JOHNS HOPKINS HOSPITAL   (United States)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

^j YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF ILLINOIS   (United States)

^l VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

more..

Author keywords

Adiposity; Adiposopathic dyslipidemia; Adiposopathy; Dyslipidemia; High density lipoprotein; Insulin resistance; Low density lipoprotein; Obesity; Triglycerides; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; AMFEBUTAMONE; AMFEBUTAMONE PLUS NALTREXONE; C REACTIVE PROTEIN; CERULOPLASMIN; CHOLESTEROL; COMPLEMENT FACTOR D; INTERLEUKIN 1; INTERLEUKIN 6; LIPID; LIPOPROTEIN; LORCASERIN; METALLOTHIONEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NALTREXONE; PENTRAXIN 3; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PROSTAGLANDIN E2; RANTES; RESISTIN; SERUM AMYLOID A; STROMAL CELL DERIVED FACTOR 1; TETRAHYDROLIPSTATIN; TOPIRAMATE; TRANSFORMING GROWTH FACTOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ADIPOCYTE; ADIPOSE TISSUE; AGGRESSION; AGITATION; ANOREXIA; ANXIETY; ARTHRALGIA; ARTICLE; ATHEROSCLEROSIS; BARIATRIC SURGERY; BLURRED VISION; BODY FAT; BRADYCARDIA; CARDIOVASCULAR RISK; CHOLELITHIASIS; COGNITIVE DEFECT; CONSTIPATION; COUGHING; DEFECATION URGENCY; DELUSION; DEPRESSION; DIAPHORESIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DIZZINESS; DROWSINESS; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; DYSGEUSIA; DYSLIPIDEMIA; DYSPHORIA; EDEMA; EUPHORIA; EXCITEMENT; EXERCISE; EYE REDNESS; FAT INTAKE; FATIGUE; FECES INCONTINENCE; FLATULENCE; GENETIC PREDISPOSITION; GLAUCOMA; HALLUCINATION; HEADACHE; HEART PALPITATION; HOSTILITY; HUMAN; HYPERANDROGENISM; HYPERPROLACTINEMIA; HYPERTRIGLYCERIDEMIA; IMPOTENCE; INSOMNIA; INSULIN RELEASE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY FAILURE; KINESIOTHERAPY; LIBIDO DISORDER; LIPID METABOLISM; LIVER CELL DAMAGE; MANIA; MEDICAL SOCIETY; MEMORY DISORDER; METABOLIC ACIDOSIS; MIGRAINE; MOOD CHANGE; MOOD DISORDER; MYALGIA; MYOPIA; NAUSEA; NEPHROLITHIASIS; NERVOUSNESS; NONHUMAN; NUTRITION; OBESITY; PANCREAS ISLET CELL; PANIC; PARANOIA; PARESTHESIA; PATHOGENESIS; PHARYNGITIS; PHOTOPHOBIA; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PRURITUS; PSYCHOMOTOR DISORDER; PSYCHOSIS; SEDENTARY LIFESTYLE; SEIZURE; SIDE EFFECT; SKELETAL MUSCLE; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE ATTEMPT; TACHYCARDIA; TINNITUS; TREMOR; URINARY FREQUENCY; URTICARIA; WEIGHT REDUCTION; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADIPOSITY; ADIPOSOPATHIC DYSLIPIDEMIA; ADIPOSOPATHY; DYSLIPIDEMIA; HIGH-DENSITY LIPOPROTEIN; INSULIN RESISTANCE; LOW-DENSITY LIPOPROTEIN; OBESITY; TRIGLYCERIDES; TYPE 2 DIABETES MELLITUS;

ADIPOSITY; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; INSULIN RESISTANCE; OBESITY; TRIGLYCERIDES;

ANIMALIA;

EID: 84880917866     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2013.04.001     Document Type: Article

References (384)

1. H.E. Bays "Sick fat," metabolic disease, and atherosclerosis Am J Med 122 2009 S26 S37
2. K.M. Flegal, M.D. Carroll, B.K. Kit, and C.L. Ogden Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010 JAMA 307 2012 491 497
3. S. Carmienke, M.H. Freitag, and T. Pischon General and abdominal obesity parameters and their combination in relation to mortality: a systematic review and meta-regression analysis Eur J Clin Nutr 2013 20 61
4. National Heart, Lung, and Blood Institue. Classification of Overweight and Obesity by BMI, Waist Circumference, and Associated Disease Risks. http://www.nhlbi.nih.gov/health/public/heart/obesity/lose-wt/bmi-dis.htm. Accessed March, 2013.
5. A.M. Sharma, and R.F. Kushner A proposed clinical staging system for obesity Int J Obes (Lond) 33 2009 289 295
6. H.E. Bays Adiposopathy: Is "sick fat" a cardiovascular disease? J Am Coll Cardiol 57 2011 2461 2473
7. National Heart, Lung, and Blood Institute. The Practical Guide: Identification, evaluation and treatment of overweight and obesity in adults. http://www.nhlbi.nih.gov/guidelines/obesity/prctgd-c.pdf. Published Oct 2000. Accessed July 7 2012.
8. World Health Organization. Obesity and Overweight Fact Sheet Number 311: http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed July 9, 2012.
9. World Health Organization. Diabetes Fact Sheet Number 312. http://www.who.int/mediacentre/factsheets/fs312/en/ Accessed July 9, 2012.
10. E.S. Ford, W.H. Giles, and A.H. Mokdad Increasing prevalence of the metabolic syndrome among U.S. adults Diabetes Care 27 2004 2444 2449 (Pubitemid 39281399)
11. H.E. Bays, J.M. Gonzalez-Campoy, and R.R. Henry Is adiposopathy (sick fat) an endocrine disease? Int J Clin Pract 62 2008 1474 1483
12. H.E. Bays, J.M. Gonzalez-Campoy, and G.A. Bray Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity Expert Rev Cardiovasc Ther 6 2008 343 368
13. H.E. Bays Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary heart disease: treating "sick fat" through improving fat function with anti-diabetes therapies Am J Cardiol 110 2012 4B 12B
14. Y.H. Yu, and H.N. Ginsberg Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue Circ Res 96 2005 1042 1052 (Pubitemid 40791376)
15. H.E. Bays, K.M. Fox, and S. Grandy Anthropometric measurements and diabetes mellitus: clues to the "pathogenic" and " protective" potential of adipose tissue Metab Syndr Relat Disord 8 2010 307 315
16. P.J. Randle, P.B. Garland, C.N. Hales, and E.A. Newsholme The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus Lancet 1 1963 785 789
17. G.I. Shulman, D.L. Rothman, T. Jue, P. Stein, R.A. DeFronzo, and R.G. Shulman Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy N Engl J Med 322 1990 223 228 (Pubitemid 20034509)
18. D.L. Rothman, I. Magnusson, and G. Cline Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus Proc Natl Acad Sci U S A 92 1995 983 987
19. D.L. Rothman, R.G. Shulman, and G.I. Shulman 31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate. Evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes mellitus J Clin Invest 89 1992 1069 1075
20. G.W. Cline, K.F. Petersen, and M. Krssak Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes N Engl J Med 341 1999 240 246 (Pubitemid 29334522)
21. A. Dresner, D. Laurent, and M. Marcucci Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity J Clin Invest 103 1999 253 259 (Pubitemid 29053143)
22. M.E. Griffin, M.J. Marcucci, and G.W. Cline Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade Diabetes 48 1999 1270 1274 (Pubitemid 29241025)
23. M. Roden, T.B. Price, and G. Perseghin Mechanism of free fatty acid-induced insulin resistance in humans J Clin Invest 97 1996 2859 2865 (Pubitemid 26197099)
24. T.P. Ciaraldi, L. Abrams, S. Nikoulina, S. Mudaliar, and R.R. Henry Glucose transport in cultured human skeletal muscle cells. Regulation by insulin and glucose in nondiabetic and non-insulin-dependent diabetes mellitus subjects J Clin Invest 96 1995 2820 2827
25. W.T. Garvey, L. Maianu, J.H. Zhu, G. Brechtel-Hook, P. Wallace, and A.D. Baron Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance J Clin Invest 101 1998 2377 2386 (Pubitemid 28270432)
26. R.T. Watson, and J.E. Pessin GLUT4 translocation: The last 200 nanometers Cellular Signal 19 2007 2209 2217 (Pubitemid 47361681)
27. M.J. Saad, F. Folli, J.A. Kahn, and C.R. Kahn Modulation of insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone-treated rats J Clin Invest 92 1993 2065 2072 (Pubitemid 23304579)
28. F. Folli, M.J. Saad, J.M. Backer, and C.R. Kahn Regulation of phosphatidylinositol 3-kinase activity in liver and muscle of animal models of insulin-resistant and insulin-deficient diabetes mellitus J Clin Invest 92 1993 1787 1794 (Pubitemid 23304544)
29. M. Krssak, K. Falk Petersen, and A. Dresner Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study Diabetologia 42 1999 113 116 (Pubitemid 29039748)
30. C. Yu, Y. Chen, and G.W. Cline Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle J Biol Chem 277 2002 50230 50236 (Pubitemid 36042170)
31. S.I. Itani, N.B. Ruderman, F. Schmieder, and G. Boden Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha Diabetes 51 2002 2005 2011 (Pubitemid 34729001)
32. Szendroedi J, Yoshimura T, Phielix E, et al. The role of diacylglycerol concentrations in the development of lipid-mediated insulin resistance in human skeletal muscle. European Association for the Study of Diabetes. Lisbon, Portrugal 2011.
33. J.K. Kim, J.J. Fillmore, and Y. Chen Tissue-specific overexpression of lipoprotein lipase causes tissue- specific insulin resistance Proc Natl Acad Sci U S A 98 2001 7522 7527 (Pubitemid 32567981)
34. H. Wang, L.A. Knaub, and D.R. Jensen Skeletal muscle-specific deletion of lipoprotein lipase enhances insulin signaling in skeletal muscle but causes insulin resistance in liver and other tissues Diabetes 58 2009 116 124
35. J.R. Goudriaan, V.E.H. Dahlmans, and B. Teusink CD36 deficiency increases insulin sensitivity in muscle, but induces insulin resistance in the liver in mice J Lipid Res 44 2003 2270 2277 (Pubitemid 38082485)
36. T. Hajri, X.X. Han, A. Bonen, and N.A. Abumrad Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice J Clin Invest 109 2002 1381 1389 (Pubitemid 34546903)
37. J.K. Kim, R.E. Gimeno, and T. Higashimori Inactivation of fatty acid transport protein 1 prevents fat-induced insulin resistance in skeletal muscle J Clin Invest 113 2004 756 763 (Pubitemid 38544169)
38. C.S. Choi, J.J. Fillmore, and J.K. Kim Overexpression of uncoupling protein 3 in skeletal muscle protects against fat-induced insulin resistance J Clin Invest 117 2007 1995 2003 (Pubitemid 47036334)
39. C.S. Choi, D.B. Savage, and L. Abu-Elheiga Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity Proc Natl Acad Sci U S A 104 2007 16480 16485 (Pubitemid 350211044)
40. K.L. Hoehn, N. Turner, and M.M. Swarbrick Acute or chronic upregulation of mitochondrial fatty acid oxidation has no net effect on whole-body energy expenditure or adiposity Cell Metab 11 2010 70 76
41. S.F. Previs, D.J. Withers, and J.M. Ren Contrasting effects of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism in vivo J Biol Chem 275 2000 38990 38994 (Pubitemid 32058910)
42. V.T. Samuel, Z.X. Liu, and X. Qu Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease J Biol Chem 279 2004 32345 32353 (Pubitemid 39014687)
43. M. Krssak, A. Brehm, and E. Bernroider Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes Diabetes 53 2004 3048 3056 (Pubitemid 39564478)
44. I. Magnusson, D.L. Rothman, L.D. Katz, R.G. Shulman, and G.I. Shulman Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study J Clin Invest 90 1992 1323 1327
45. T. Matsuzaka, H. Shimano, and N. Yahagi Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance Nat Med 13 2007 1193 1202 (Pubitemid 47530641)
46. D.B. Savage, C.S. Choi, and V.T. Samuel Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 J Clin Invest 116 2006 817 824 (Pubitemid 43326891)
47. G.M. Varela, D.A. Antwi, and R. Dhir Inhibition of ADRP prevents diet-induced insulin resistance Am J Physiol Gastrointest Liver Physiol 295 2008 G621 G628
48. D. Zhang, Z.-X. Liu, and C.S. Choi Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance Proc Natl Acad Sci U S A 104 2007 17075 17080 (Pubitemid 350210994)
49. S.T. Crooke Progress in antisense technology Annu Rev Med 55 2004 61 95 (Pubitemid 38316716)
50. N. Kumashiro, D.M. Erion, and D. Zhang Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease Proc Natl Acad Sci U S A 108 2011 16381 16385
51. J. Hirosumi, G. Tuncman, and L. Chang A central role for JNK in obesity and insulin resistance Nature 420 2002 333 336 (Pubitemid 35398190)
52. U. Ozcan, Q. Cao, and E. Yilmaz Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes Science 306 2004 457 461 (Pubitemid 39372439)
53. M.F. Gregor, L. Yang, and E. Fabbrini Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss Diabetes 58 2009 693 700
54. U. Ozcan, E. Yilmaz, and L. Ozcan Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes Science 313 2006 1137 1140 (Pubitemid 44300242)
55. M.W. Lee, D. Chanda, and J. Yang Regulation of hepatic gluconeogenesis by an ER-bound transcription factor, CREBH Cell metab 11 2010 331 339
56. K. Zhang, X. Shen, and J. Wu Endoplasmic reticulum stress activates cleavage of CREBH to induce a systemic inflammatory response Cell 124 2006 587 599 (Pubitemid 43199443)
57. R.P. Wildman, P. Muntner, and K. Reynolds The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004) Arch Intern Med 168 2008 1617 1624
58. M. Chandalia, P. Lin, and T. Seenivasan Insulin resistance and body fat distribution in South Asian men compared to Caucasian men PLoS One 2 2007 e812
59. E.H. Livingston, M. Chandalia, and N. Abate Do current body mass index criteria for obesity surgery reflect cardiovascular risk? Surg Obes Relat Dis 3 2007 577 585 (Pubitemid 350091415)
60. N. Ruderman, D. Chisholm, X. Pi-Sunyer, and S. Schneider The metabolically obese, normal-weight individual revisited Diabetes 47 1998 699 713 (Pubitemid 28201798)
61. K.G. Alberti, P. Zimmet, J. Shaw, and Group IDFETFC The metabolic syndrome-a new worldwide definition Lancet 366 2005 1059 1062 (Pubitemid 41338752)
62. M. Chandalia, S.M. Grundy, B. Adams-Huet, and N. Abate Ethnic differences in the frequency of ENPP1/PC1 121Q genetic variant in the Dallas Heart Study cohort J Diabetes Complications 21 2007 143 148 (Pubitemid 46687070)
63. J. Liang, M. Fu, E. Ciociola, M. Chandalia, and N. Abate Role of ENPP1 on adipocyte maturation PLoS One 2 2007 e882
64. W. Pan, E. Ciociola, and M. Saraf Metabolic consequences of ENPP1 overexpression in adipose tissue Am J Physiol Endocrinol Metab 301 2011 E901 E911
65. M. Chandalia, H. Davila, and W. Pan Adipose tissue dysfunction in humans: a potential role for the transmembrane protein ENPP1 J Clin Endocrinol Metab 97 2012 4663 4672
66. B.V. Howard, G. Ruotolo, and D.C. Robbins Obesity and dyslipidemia Endocrinol Metab Clin North Am 32 2003 855 867 (Pubitemid 38029984)
67. R.J. Havel, V.G. Shore, B. Shore, and D.M. Bier Role of specific glycopeptides of human serum lipoproteins in the activation of lipoprotein lipase Circ Res 27 1970 595 600
68. K.M. Botham, E.H. Moore, C. De Pascale, and F. Bejta The induction of macrophage foam cell formation by chylomicron remnants Biochem Soc Trans 35 2007 454 458 (Pubitemid 46975050)
69. J.R. McNamara, J.L. Jenner, Z. Li, P.W. Wilson, and E.J. Schaefer Change in LDL particle size is associated with change in plasma triglyceride concentration Arterioscler Thromb 12 1992 1284 1290
70. E.J. Schaefer, J.R. McNamara, and P.K. Shah Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study Diabetes Care 25 2002 989 994 (Pubitemid 41110483)
71. J. Regnstrom, J. Nilsson, P. Tornvall, C. Landou, and A. Hamsten Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man Lancet 339 1992 1183 1186
72. M.A. Austin, M.C. King, K.M. Vranizan, and R.M. Krauss Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk Circulation 82 1990 495 506 (Pubitemid 20257828)
73. R.S. Rosenson, and G.D. Lowe Effects of lipids and lipoproteins on thrombosis and rheology Atherosclerosis 140 1998 271 280 (Pubitemid 28535318)
74. A.H. Seplowitz, S. Chien, and F.R. Smith Effects of lipoproteins on plasma viscosity Atherosclerosis 38 1981 89 95 (Pubitemid 11138610)
75. R.J. Havel Pathogenesis, differentiation and management of hypertriglyceridemia Adv Intern Med 15 1969 117 154
76. C.J. Glueck, D. Scheel, J. Fishback, and P. Steiner Estrogen-induced pancreatitis in patients with previously covert familial type V hyperlipoproteinemia Metabolism 21 1972 657 666
77. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
78. The Emerging Risk Factors Collaboration Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
79. The FIELD Investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
80. The ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
81. M.H. Davidson, C.M. Ballantyne, and T.A. Jacobson Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists J Clin Lipidol 5 2011 338 367
82. M. Miller, N.J. Stone, and C. Ballantyne Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association Circulation 123 2011 2292 2333
83. H.E. Bays Fish Oils in the Treatment of Dyslipidemia and Cardiovascular Disease: Chapter 21 J. Peter O Kwiterovich, The John Hopkins Textbook of Dyslipidemia 2010 PA Lippincott Williams & Wilkins Philadelphia
84. M. Miller Current perspectives on the management of hypertriglyceridemia Am Heart J 140 2000 232 240 (Pubitemid 30641584)
85. J. de Graaf, P. Couture, and A. Sniderman A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias Nat Clin Pract Endocrinol Metab 4 2008 608 618
86. J.L. Goldstein, H.G. Schrott, W.R. Hazzard, E.L. Bierman, and A.G. Motulsky Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia J Clin Invest 52 1973 1544 1568
87. J.D. Brunzell, H.G. Schrott, A.G. Motulsky, and E.L. Bierman Myocardial infarction in the familial forms of hypertriglyceridemia Metabolism 25 1976 313 320
88. P.W. Wilson, R.B. D'Agostino, H. Parise, L. Sullivan, and J.B. Meigs Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus Circulation 112 2005 3066 3072 (Pubitemid 43113437)
89. H.M. Lakka, D.E. Laaksonen, and T.A. Lakka The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men JAMA 288 2002 2709 2716 (Pubitemid 35403784)
90. A. Onat, G. Can, H. Kaya, and G. Hergenc "Atherogenic index of plasma" (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events J Clin Lipidol 4 2010 89 98
91. T. McLaughlin, F. Abbasi, K. Cheal, J. Chu, C. Lamendola, and G. Reaven Use of metabolic markers to identify overweight individuals who are insulin resistant Ann Intern Med 139 2003 802 809
92. V. Bittner, B.D. Johnson, and I. Zineh The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Women's Ischemia Syndrome Evaluation (WISE) Am Heart J 157 2009 548 555
93. J.D. Sparks, C.E. Sparks, and K. Adeli Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia Arterioscler Thromb Vasc Biol 32 2012 2104 2112
94. J.B. Moore Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome Proc Nutr Soc 69 2010 211 220
95. G. Targher, C.P. Day, and E. Bonora Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease N Engl J Med 363 2010 1341 1350
96. H.C. Kim, D.J. Kim, and K.B. Huh Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome Atherosclerosis 204 2009 521 525
97. Y.J. Lee, J.Y. Shim, and B.S. Moon The relationship between arterial stiffness and nonalcoholic fatty liver disease Dig Dis Sci 57 2012 196 203
98. W.P. Castelli Cholesterol and lipids in the risk of coronary artery disease-the Framingham Heart Study Can J Cardiol 4 Suppl A 1988 5A 10A
99. G. Assmann, P. Cullen, and H. Schulte The Munster Heart Study (PROCAM). Results of follow-up at 8 years Eur Heart J 19 Suppl A 1998 A2 11
100. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
101. J.C. Tardif, J. Gregoire, and P.L. L'Allier Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial JAMA 297 2007 1675 1682 (Pubitemid 46631626)
102. S.E. Nissen, T. Tsunoda, and E.M. Tuzcu Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial JAMA 290 2003 2292 2300 (Pubitemid 37430562)
103. S.J. Nicholls, E.M. Tuzcu, and I. Sipahi Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis JAMA 297 2007 499 508 (Pubitemid 46220805)
104. C.M. Ballantyne, J.S. Raichlen, and S.J. Nicholls Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden Circulation 117 2008 2458 2466 (Pubitemid 351670452)
105. B. Brown, X. Zhao, and M. Cheung Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence Journal of Clinical Lipidology 1 2007 88 94 (Pubitemid 46710835)
106. I. Goldenberg, U. Goldbourt, V. Boyko, S. Behar, and H. Reicher-Reiss Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial) Am J Cardiol 97 2006 466 471 (Pubitemid 43190032)
107. Y. Cui, D.J. Watson, and C.J. Girman Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study) Am J Cardiol 104 2009 829 834
108. S.E. Nissen, S.J. Nicholls, and K. Wolski Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial JAMA 299 2008 1561 1573 (Pubitemid 351482795)
109. T. Mazzone, P.M. Meyer, and S.B. Feinstein Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial JAMA 296 2006 2572 2581 (Pubitemid 44903861)
110. P.J. Barter, M. Caulfield, and M. Eriksson Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122 (Pubitemid 350146106)
111. G.G. Schwartz, A.G. Olsson, and M. Abt Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome N Engl J Med 367 2012 2089 2099
112. W.E. Boden, J.L. Probstfield, and T. Anderson Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
113. News Release, December 20, 2012: Merck Announces HPS2-THRIVE Study of TREDAPTIVE™ (Extended Release Niacin/Laropiprant) Did Not Achieve Primary Endpoint. http://www.thrivestudy.org/HPS2THRIVE%20RELEASEUSWIREVERSIONfinal.pdf. Accessed on February 4, 2013.
114. T. Vaisar, S. Pennathur, and P.S. Green Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL J Clin Invest 117 2007 746 756 (Pubitemid 46348533)
115. G. Assmann, and J.R. Nofer Atheroprotective effects of high-density lipoproteins Annu Rev Med 54 2003 321 341 (Pubitemid 37386400)
116. P.P. Toth Activation of intracellular signaling systems by high-density lipoproteins J Clin Lipidol 4 2010 376 381
117. A.V. Khera, M. Cuchel, and M. de la Llera-Moya Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis N Engl J Med 364 2011 127 135
118. L. Calabresi, M. Gomaraschi, and G. Franceschini Endothelial protection by high-density lipoproteins: from bench to bedside Arterioscler Thromb Vasc Biol 23 2003 1724 1731 (Pubitemid 37254854)
119. P. Toth High-density lipoprotein: epidemiology, metabolism, and antiatherogenic effects Dis Mon 47 2001 365 416
120. B.J. Ansell, G.C. Fonarow, and A.M. Fogelman High-density Lipoprotein:Is It Always Atheroprotective? Curr Atheroscler Rep 8 2006 405 411
121. H.B. Hubert, M. Feinleib, P.M. McNamara, and W.P. Castelli Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study Circulation 67 1983 968 977 (Pubitemid 13080473)
122. J.R. Sowers Obesity as a cardiovascular risk factor Am J Med 115 Suppl 8A 2003 37S 41S
123. D. Weissglas-Volkov, and P. Pajukanta Genetic causes of high and low serum HDL-cholesterol J Lipid Res 51 2010 2032 2057
124. M.P. Stern, K. Williams, and S.M. Haffner Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 136 2002 575 581 (Pubitemid 34407041)
125. S. Rashid, and J. Genest Effect of obesity on high-density lipoprotein metabolism Obesity (Silver Spring) 15 2007 2875 2888 (Pubitemid 351256646)
126. C.M. Aguilera, M. Gil-Campos, R. Canete, and A. Gil Alterations in plasma and tissue lipids associated with obesity and metabolic syndrome Clin Sci (Lond) 114 2008 183 193 (Pubitemid 351293994)
127. M.C. Jong, M.H. Hofker, and L.M. Havekes Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3 Arterioscler Thromb Vasc Biol 19 1999 472 484 (Pubitemid 29135144)
128. V. Sukonina, A. Lookene, T. Olivecrona, and G. Olivecrona Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue Proc Natl Acad Sci U S A 103 2006 17450 17455 (Pubitemid 44788989)
129. A. Koster, Y.B. Chao, and M. Mosior Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism Endocrinology 146 2005 4943 4950 (Pubitemid 41446633)
130. L. Lichtenstein, J.F. Berbee, and S.J. van Dijk Angptl4 upregulates cholesterol synthesis in liver via inhibition of LPL- and HL-dependent hepatic cholesterol uptake Arterioscler Thromb Vasc Biol 27 2007 2420 2427 (Pubitemid 350203959)
131. K. Inukai, Y. Nakashima, and M. Watanabe ANGPTL3 is increased in both insulin-deficient and -resistant diabetic states Biochem Biophys Res Commun 317 2004 1075 1079 (Pubitemid 38496419)
132. Y. Zhang, F.C. McGillicuddy, and C.C. Hinkle Adipocyte modulation of high-density lipoprotein cholesterol Circulation 121 2010 1347 1355
133. A.D. Mooradian, M.J. Haas, K.R. Wehmeier, and N.C. Wong Obesity-related changes in high-density lipoprotein metabolism Obesity (Silver Spring) 16 2008 1152 1160 (Pubitemid 351770500)
134. A.D. Mooradian, M.J. Haas, and N.C. Wong Transcriptional control of apolipoprotein A-I gene expression in diabetes Diabetes 53 2004 513 520 (Pubitemid 38270617)
135. J.K. Lam, S. Matsubara, K. Mihara, X.L. Zheng, A.D. Mooradian, and N.C. Wong Insulin induction of apolipoprotein AI, role of Sp1 Biochemistry (Mosc) 42 2003 2680 2690 (Pubitemid 36330622)
136. K. Murao, Y. Wada, T. Nakamura, A.H. Taylor, A.D. Mooradian, and N.C. Wong Effects of glucose and insulin on rat apolipoprotein A-I gene expression J Biol Chem 273 1998 18959 18965 (Pubitemid 28366285)
137. M.J. Haas, M. Horani, A. Mreyoud, B. Plummer, N.C. Wong, and A.D. Mooradian Suppression of apolipoprotein AI gene expression in HepG2 cells by TNF alpha and IL-1beta Biochim Biophys Acta 1623 2003 120 128 (Pubitemid 37315668)
138. Q. Zhu, K. Yamagata, and A. Miura T130I mutation in HNF-4alpha gene is a loss-of-function mutation in hepatocytes and is associated with late-onset Type 2 diabetes mellitus in Japanese subjects Diabetologia 46 2003 567 573 (Pubitemid 36577802)
139. J.A. Krikken, R.T. Gansevoort, and R.P. Dullaart Lower HDL-C and apolipoprotein A-I are related to higher glomerular filtration rate in subjects without kidney disease J Lipid Res 51 2010 1982 1990
140. A. Chagnac, T. Weinstein, A. Korzets, E. Ramadan, J. Hirsch, and U. Gafter Glomerular hemodynamics in severe obesity American Journal of Physiology - Renal Physiology 278 2000 F817 F822
141. G. Bayliss, L.A. Weinrauch, and J.A. D'Elia Pathophysiology of obesity-related renal dysfunction contributes to diabetic nephropathy Curr Diab Rep 12 2012 440 446
142. A. Kontush, and M.J. Chapman Why is HDL functionally deficient in type 2 diabetes? Curr Diab Rep 8 2008 51 59 (Pubitemid 351384876)
143. M. Mastorikou, M. Mackness, and B. Mackness Defective metabolism of oxidized phospholipid by HDL from people with type 2 diabetes Diabetes 55 2006 3099 3103 (Pubitemid 44923648)
144. A.N. Hoofnagle, M. Wu, and A.K. Gosmanova Low clusterin levels in high-density lipoprotein associate with insulin resistance, obesity, and dyslipoproteinemia Arterioscler Thromb Vasc Biol 30 2010 2528 2534
145. M.E. Roehrich, V. Mooser, and V. Lenain Insulin-secreting beta-cell dysfunction induced by human lipoproteins J Biol Chem 278 2003 18368 18375 (Pubitemid 36799458)
146. A. Abderrahmani, G. Niederhauser, and D. Favre Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells Diabetologia 50 2007 1304 1314 (Pubitemid 46701553)
147. S. Rutti, J.A. Ehses, and R.A. Sibler Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells Endocrinology 150 2009 4521 4530
148. L.R. Brunham, J.K. Kruit, and T.D. Pape Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment Nat Med 13 2007 340 347 (Pubitemid 46376682)
149. M.A. Fryirs, P.J. Barter, and M. Appavoo Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion Arterioscler Thromb Vasc Biol 30 2010 1642 1648
150. R. Han, R. Lai, and Q. Ding Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolism Diabetologia 50 2007 1960 1968 (Pubitemid 47222866)
151. B.G. Drew, S.J. Duffy, and M.F. Formosa High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus Circulation 119 2009 2103 2111
152. P.J. Barter, K.A. Rye, and J.C. Tardif Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial Circulation 124 2011 555 562
153. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239 (Pubitemid 38924592)
154. L.J. Aronne, W.V. Brown, and K.K. Isoldi Cardiovascular disease in obesity: A review of related risk factors and risk-reduction strategies J Clin Lipidol 1 2007 575 582 (Pubitemid 350218045)
155. W.B. Kannel, T. Gordon, and W.P. Castelli Obesity, lipids, and glucose intolerance. The Framingham Study Am J Clin Nutr 32 1979 1238 1245 (Pubitemid 9201487)
156. S. Lamon-Fava, P.W. Wilson, and E.J. Schaefer Impact of body mass index on coronary heart disease risk factors in men and women. The Framingham Offspring Study Arterioscler Thromb Vasc Biol 16 1996 1509 1515 (Pubitemid 26427605)
157. J.P. Despres, S. Moorjani, P.J. Lupien, A. Tremblay, A. Nadeau, and C. Bouchard Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease Arteriosclerosis 10 1990 497 511 (Pubitemid 20220572)
158. D. Canoy, N. Wareham, and R. Luben Serum lipid concentration in relation to anthropometric indices of central and peripheral fat distribution in 20,021 British men and women: results from the EPIC-Norfolk population-based cohort study Atherosclerosis 189 2006 420 427 (Pubitemid 44754724)
159. R.M. Krauss, and D.J. Burke Identification of multiple subclasses of plasma low density lipoproteins in normal humans J Lipid Res 23 1982 97 104 (Pubitemid 12112617)
160. A. Sniderman, S. Shapiro, D. Marpole, B. Skinner, B. Teng, and P.O. Kwiterovich Jr. Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins] Proc Natl Acad Sci U S A 77 1980 604 608 (Pubitemid 10141071)
161. W.C. Cromwell, J.D. Otvos, and M.J. Keyes LDL particle number and risk of future cardiovascular disease in the framingham offspring study - implications for LDL management J Clin Lipidol 1 2007 583 592 (Pubitemid 350215511)
162. K. Williams, A.D. Sniderman, N. Sattar, R. D'Agostino Jr., L.E. Wagenknecht, and S.M. Haffner Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS) Circulation 108 2003 2312 2316 (Pubitemid 37413535)
163. J.D. Otvos, S. Mora, I. Shalaurova, P. Greenland, R.H. Mackey, and D.C. Goff Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number J Clin Lipidol 5 2011 105 113
164. S. Koba, T. Hirano, and G. Yoshino Remarkably high prevalence of small dense low-density lipoprotein in Japanese men with coronary artery disease, irrespective of the presence of diabetes Atherosclerosis 160 2002 249 256 (Pubitemid 34076661)
165. Y.A. Kesaniemi, and S.M. Grundy Increased low density lipoprotein production associated with obesity Arteriosclerosis 3 1983 170 177 (Pubitemid 13136503)
166. H.N. Ginsberg, N.A. Le, J. Melish, D. Steinberg, and W.V. Brown Effect of a high carbohydrate diet on apoprotein-B catabolism in man Metabolism 30 1981 347 353 (Pubitemid 11101147)
167. D.C. Chan, G.F. Watts, T.G. Redgrave, T.A. Mori, and P.H. Barrett Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration Metabolism 51 2002 1041 1046
168. W.V. Brown, and M.L. Baginsky Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein Biochem Biophys Res Commun 46 1972 375 382
169. H.N. Ginsberg, N.A. Le, and I.J. Goldberg Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo J Clin Invest 78 1986 1287 1295 (Pubitemid 17181567)
170. V. Clavey, S. Lestavel-Delattre, C. Copin, J.M. Bard, and J.C. Fruchart Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E Arterioscler Thromb Vasc Biol 15 1995 963 971
171. M.J. Shin, and R.M. Krauss Apolipoprotein CIII bound to apoB-containing lipoproteins is associated with small, dense LDL independent of plasma triglyceride levels in healthy men Atherosclerosis 211 2010 337 341
172. C.O. Mendivil, E.B. Rimm, J. Furtado, S.E. Chiuve, and F.M. Sacks Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease Circulation 124 2011 2065 2072
173. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
174. A. Varanasi, A. Chaudhuri, and S. Dhindsa Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, C-reactive protein, and triglyceride concentrations Endocr Pract 17 2011 192 200
175. G. AbouRjaili, N. Shtaynberg, R. Wetz, T. Costantino, and G.S. Abela Current concepts in triglyceride metabolism, pathophysiology, and treatment Metabolism 59 2010 1210 1220
176. C. von Schacky A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels Vasc Health Risk Manag 2 2006 251 262
177. S. Wild, and C.D. Byrne The role of treatment to increase HDL-cholesterol and decrease triglyceride concentrations in prevention of coronary heart disease in Type 2 diabetes Diabet Med 21 Suppl 4 2004 8 11 (Pubitemid 39215309)
178. A. Gaw HDL-C and triglyceride levels: relationship to coronary heart disease and treatment with statins Cardiovasc Drugs Ther 17 2003 53 62 (Pubitemid 36898098)
179. E.E. Ferguson Jr. Preventing, stopping, or reversing coronary artery disease-triglyceride-rich lipoproteins and associated lipoprotein and metabolic abnormalities: the need for recognition and treatment Dis Mon 46 2000 421 503
180. H.J. Schneider, H. Glaesmer, and J. Klotsche Accuracy of anthropometric indicators of obesity to predict cardiovascular risk J Clin Endocrinol Metab 92 2007 589 594
181. J.A. Shepherd, B. Fan, and Y. Lu A multinational study to develop universal standardization of whole body bone density and composition using GE Healthcare Lunar and Hologic DXA systems J Bone Miner Res 27 10 2012 2208 2216
182. R.J. Toombs, G. Ducher, J.A. Shepherd, and M.J. De Souza The impact of recent technological advances on the trueness and precision of DXA to assess body composition Obesity (Silver Spring) 20 2012 30 39
183. E.M. Evans, M.M. Misic, and D.M. Mallard A technique to assess body composition and sarcopenia using DXA: application for an obese population Eur J Clin Nutr 64 2010 218 220
184. A. Andreoli, G. Scalzo, S. Masala, U. Tarantino, and G. Guglielmi Body composition assessment by dual-energy X-ray absorptiometry (DXA) Radiol Med 114 2009 286 300
185. J. LaForgia, J. Dollman, M.J. Dale, R.T. Withers, and A.M. Hill Validation of DXA body composition estimates in obese men and women Obesity (Silver Spring) 17 2009 821 826
186. S. Appachi, K.R. Kelly, and P.R. Schauer Reduced cardiovascular risk following bariatric surgeries is related to a partial recovery from "adiposopathy" Obes Surg 21 2011 1928 1936
187. G.D. Norata, S. Raselli, and L. Grigore Leptin:adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery Stroke 38 2007 2844 2846 (Pubitemid 47494027)
188. V.A. Moyer on behalf of the USPSTF Screening for and management of obesity in adults: U.S. preventive services task force recommendation statement Ann Intern Med 157 5 2012 373 378
189. E.J. Hendricks, and F.L. Greenway A study of abrupt phentermine cessation in patients in a weight management program Am J Ther 18 2011 292 299
190. E.J. Hendricks, F.L. Greenway, E.C. Westman, and A.K. Gupta Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity Obesity (Silver Spring) 19 12 2011 2351 2360
191. E.J. Hendricks, and R.B. Rothman Phentermine therapy for obesity does not elevate blood pressure Diabetes Obes Metab 13 2011 963 964
192. M.L. Isidro, and F. Cordido Drug treatment of obesity: established and emerging therapies Mini Rev Med Chem 9 2009 664 673
193. E. Idelevich, W. Kirch, and C. Schindler Current pharmacotherapeutic concepts for the treatment of obesity in adults Ther Adv Cardiovasc Dis 3 2009 75 90
194. D. Rucker, R. Padwal, S.K. Li, C. Curioni, and D.C. Lau Long term pharmacotherapy for obesity and overweight: updated meta-analysis BMJ 335 2007 1194 1199 (Pubitemid 350273303)
195. L.J. Aronne, A.E. Halseth, C.M. Burns, S. Miller, and L.Z. Shen Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial Obesity (Silver Spring) 18 9 2010 1739 1746
196. A.G. Powell, C.M. Apovian, and L.J. Aronne New drug targets for the treatment of obesity Clin Pharmacol Ther 90 2011 40 51
197. H.E. Bays, B. Laferrere, and J. Dixon Adiposopathy and bariatric surgery: is 'sick fat' a surgical disease? Int J Clin Pract 63 2009 1285 1300
198. J.I. Mechanick, R.F. Kushner, and H.J. Sugerman Executive summary of the recommendations of the American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient Endocr Pract 14 2008 318 336
199. T.A. Farley, and G. Van Wye Reversing the obesity epidemic: the importance of policy and policy research Am J Prev Med 43 2012 S93 S94
200. Obesity in America: what's driving the epidemic? Harv Mens Health Watch 16 2012 5 7
201. M. Mello Legal and policy approaches to the obesity epidemic Surg Obes Relat Dis 8 5 2012 507 513
202. National Heart, Lung, and Blood Institue. Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Obesity in Adults (US) Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report 1998 Sep National Heart, Lung, and Blood Institute Bethesda (MD) Available from: http://www.ncbi.nlm.nih.gov/books/NBK2003/
203. United States Gallup Poll. (http://www.gallup.com/poll/124448/In-U.S.- More-Lose-Weight-Than-Trying-To.aspx). Accessed December 2012.
204. G. Zhao, E.S. Ford, C. Li, and A.H. Mokdad Weight control behaviors in overweight/obese U.S. adults with diagnosed hypertension and diabetes Cardiovasc Diabetol 8 2009 13
205. M.J. Franz, J.J. VanWormer, and A.L. Crain Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up J Am Diet Assoc 107 2007 1755 1767 (Pubitemid 47464109)
206. M.L. Dansinger, A. Tatsioni, J.B. Wong, M. Chung, and E.M. Balk Meta-analysis: the effect of dietary counseling for weight loss Ann Intern Med 147 2007 41 50 (Pubitemid 351664633)
207. A.M. Dattilo, and P.M. Kris-Etherton Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis Am J Clin Nutr 56 1992 320 328
208. S. Tonstad, and J.P. Despres Treatment of lipid disorders in obesity Expert Rev Cardiovasc Ther 9 2011 1069 1080
209. A.J. Nordmann, A. Nordmann, and M. Briel Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials Arch Intern Med 166 2006 285 293 (Pubitemid 43244316)
210. T.P. Wycherley, L.J. Moran, P.M. Clifton, M. Noakes, and G.D. Brinkworth Effects of energy-restricted high-protein, low-fat compared with standard-protein, low-fat diets: a meta-analysis of randomized controlled trials Am J Clin Nutr 96 2012 1281 1298
211. M.L. Dansinger, J.A. Gleason, J.L. Griffith, H.P. Selker, and E.J. Schaefer Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial JAMA 293 2005 43 53 (Pubitemid 40066698)
212. G.D. Foster, H.R. Wyatt, and J.O. Hill A randomized trial of a low-carbohydrate diet for obesity N Engl J Med 348 2003 2082 2090 (Pubitemid 36583303)
213. C.D. Gardner, A. Kiazand, and S. Alhassan Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial JAMA 297 2007 969 977 (Pubitemid 46376751)
214. D.J. Jenkins, P.J. Jones, and B. Lamarche Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial JAMA 306 2011 831 839
215. F.M. Sacks, G.A. Bray, and V.J. Carey Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates N Engl J Med 360 2009 859 873
216. I. Shai, D. Schwarzfuchs, and Y. Henkin Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet N Engl J Med 359 2008 229 241 (Pubitemid 352008438)
217. C.B. Ebbeling, J.F. Swain, and H.A. Feldman Effects of dietary composition on energy expenditure during weight-loss maintenance JAMA 307 2012 2627 2634
218. N.J. Davis, N. Tomuta, and C. Schechter Comparative study of the effects of a 1-year dietary intervention of a low-carbohydrate diet versus a low-fat diet on weight and glycemic control in type 2 diabetes Diabetes Care 32 2009 1147 1152
219. L. Stern, N. Iqbal, and P. Seshadri The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial Ann Intern Med 140 2004 778 785
220. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults-The Evidence Report. National Institutes of Health Obes Res 6 Suppl 2 1998 51S 209S
221. J. Bond Brill, A.C. Perry, L. Parker, A. Robinson, and K. Burnett Dose-response effect of walking exercise on weight loss. How much is enough? Int J Obes Relat Metab Disord 26 2002 1484 1493 (Pubitemid 36005779)
222. M. Christ, C. Iannello, P.G. Iannello, and W. Grimm Effects of a weight reduction program with and without aerobic exercise in the metabolic syndrome Int J Cardiol 97 2004 115 122 (Pubitemid 39178532)
223. J.E. Donnelly, S.N. Blair, and J.M. Jakicic American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults Med Sci Sports Exerc 41 2009 459 471
224. K.E. Foster-Schubert, C.M. Alfano, and C.R. Duggan Effect of diet and exercise, alone or combined, on weight and body composition in overweight-to-obese postmenopausal women Obesity (Silver Spring) 20 2012 1628 1638
225. C. Bouchard, A. Tremblay, and J.P. Despres The response to exercise with constant energy intake in identical twins Obes Res 2 1994 400 410
226. R. Ross, J.A. Freeman, and I. Janssen Exercise alone is an effective strategy for reducing obesity and related comorbidities Exerc Sport Sci Rev 28 2000 165 170
227. J.M. Jakicic, A.D. Otto, and W. Lang The effect of physical activity on 18-month weight change in overweight adults Obesity (Silver Spring) 19 2011 100 109
228. T. You, K.M. Murphy, M.F. Lyles, J.L. Demons, L. Lenchik, and B.J. Nicklas Addition of aerobic exercise to dietary weight loss preferentially reduces abdominal adipocyte size Int J Obes (Lond) 30 2006 1211 1216 (Pubitemid 44141609)
229. J.C. Murphy, J.L. McDaniel, K. Mora, D.T. Villareal, L. Fontana, and E.P. Weiss Preferential reductions in intermuscular and visceral adipose tissue with exercise-induced weight loss compared with calorie restriction J Appl Physiol 112 2012 79 85
230. M.T. Durheim, C.A. Slentz, L.A. Bateman, S.K. Mabe, and W.E. Kraus Relationships between exercise-induced reductions in thigh intermuscular adipose tissue, changes in lipoprotein particle size, and visceral adiposity Am J Physiol Endocrinol Metab 295 2008 E407 E412
231. J.E. Donnelly, J.O. Hill, and D.J. Jacobsen Effects of a 16-month randomized controlled exercise trial on body weight and composition in young, overweight men and women: the Midwest Exercise Trial Arch Intern Med 163 2003 1343 1350 (Pubitemid 36676200)
232. J.H. Wilmore, J.P. Despres, and P.R. Stanforth Alterations in body weight and composition consequent to 20 wk of endurance training: the HERITAGE Family Study Am J Clin Nutr 70 1999 346 352 (Pubitemid 29407154)
233. D.L. Ballor, and R.E. Keesey A meta-analysis of the factors affecting exercise-induced changes in body mass, fat mass and fat-free mass in males and females Int J Obes 15 1991 717 726
234. R. Ross, I. Janssen, and J. Dawson Exercise-induced reduction in obesity and insulin resistance in women: a randomized controlled trial Obes Res 12 2004 789 798 (Pubitemid 41127314)
235. I. Giannopoulou, L.L. Ploutz-Snyder, and R. Carhart Exercise is required for visceral fat loss in postmenopausal women with type 2 diabetes J Clin Endocrinol Metab 90 2005 1511 1518 (Pubitemid 40464012)
236. U. Ekelund, H. Besson, and J. Luan Physical activity and gain in abdominal adiposity and body weight: prospective cohort study in 288,498 men and women Am J Clin Nutr 93 2011 826 835
237. R.H. Olsen, R. Krogh-Madsen, C. Thomsen, F.W. Booth, and B.K. Pedersen Metabolic responses to reduced daily steps in healthy nonexercising men JAMA 299 2008 1261 1263 (Pubitemid 351439093)
238. B.K. Pedersen The diseasome of physical inactivity-and the role of myokines in muscle-fat cross talk J Physiol 587 2009 5559 5568
239. M.L. Mestek Physical activity, blood lipids, and lipoproteins Am J Lifestyle Med 3 2009 279 283
240. J.L. Durstine, P.W. Grandjean, P.G. Davis, M.A. Ferguson, N.L. Alderson, and K.D. DuBose Blood lipid and lipoprotein adaptations to exercise: a quantitative analysis Sports Med 31 2001 1033 1062 (Pubitemid 34017009)
241. W.E. Kraus, J.A. Houmard, and B.D. Duscha Effects of the amount and intensity of exercise on plasma lipoproteins N Engl J Med 347 2002 1483 1492 (Pubitemid 35257587)
242. J.F. Trejo-Gutierrez, and G. Fletcher Impact of exercise on blood lipids and lipoproteins J Clin Lipidol 1 2007 175 181 (Pubitemid 47055293)
243. W.E. Kraus, and C.A. Slentz Exercise training, lipid regulation, and insulin action: a tangled web of cause and effect Obesity (Silver Spring) 17 Suppl 3 2009 S21 S26
244. R.W. Haltom, R.R. Kraemer, R.A. Sloan, E.P. Hebert, K. Frank, and J.L. Tryniecki Circuit weight training and its effects on excess postexercise oxygen consumption Med Sci Sports Exerc 31 1999 1613 1618
245. A.G. Monteiro, D.A. Alveno, and M. Prado Acute physiological responses to different circuit training protocols J Sports Med Phys Fitness 48 2008 438 442
246. B. Fletcher, K. Berra, and P. Ades Managing abnormal blood lipids: a collaborative approach Circulation 112 2005 3184 3209 (Pubitemid 43113447)
247. I.A. Al-Shayji, M.J. Caslake, and J.M. Gill Effects of moderate exercise on VLDL(1) and Intralipid kinetics in overweight/obese middle-aged men Am J Physiol Endocrinol Metab 302 2012 E349 E355
248. N.P. Greene, S.E. Martin, and S.F. Crouse Acute exercise and training alter blood lipid and lipoprotein profiles differently in overweight and obese men and women Obesity (Silver Spring) 20 2012 1618 1627
249. C.A. Slentz, J.A. Houmard, and W.E. Kraus Modest exercise prevents the progressive disease associated with physical inactivity Exerc Sport Sci Rev 35 2007 18 23 (Pubitemid 46084791)
250. American College of Sports Medicine Guidelines for Exercise Testing and Prescription, 9th Edition M. Whaley, 2013 Lippincott Williams and Wilkins Philadelphia
251. National Institutes of Health news release; October 19, 2012. Weight loss does not lower heart disease risk from type 2 diabetes. http://www.nih.gov/ news/health/oct2012/niddk-19.htm. Accessed February 4, 2013.
252. F.L. Greenway, and M.K. Caruso Safety of obesity drugs Expert Opin Drug Saf 4 2005 1083 1095 (Pubitemid 41671605)
253. Y.H. Zhou, X.Q. Ma, and C. Wu Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials PLoS One 7 2012 e39062
254. H. Bays Adiposopathy: the endocannabinoid system as a therapeutic treatment target for dysfunctional 'sick' fat Californian J Health Promot 19 2007 32 39
255. H.E. Bays, and K.M. Gadde Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity Drugs Today (Barc) 47 2011 903 914
256. H. Bays Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease Expert Rev Cardiovasc Ther 8 2010 1777 1801
257. K.A. Varady, L. Tussing, S. Bhutani, and C.L. Braunschweig Degree of weight loss required to improve adipokine concentrations and decrease fat cell size in severely obese women Metabolism 58 2009 1096 1101
258. R.E. Ratner An update on the Diabetes Prevention Program Endocr Pract 12 Suppl 1 2006 20 24 (Pubitemid 44963606)
259. K.K. Kim, H.J. Cho, H.C. Kang, B.B. Youn, and K.R. Lee Effects on weight reduction and safety of short-term phentermine administration in Korean obese people Yonsei Med J 47 2006 614 625 (Pubitemid 44697292)
260. H.E. Bays, A.P. Tighe, R. Sadovsky, and M.H. Davidson Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications Expert Rev Cardiovasc Ther 6 2008 391 409
261. B. Hutton, and D. Fergusson Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials Am J Clin Nutr 80 2004 1461 1468 (Pubitemid 41103841)
262. D.E. Kelley, L.H. Kuller, T.M. McKolanis, P. Harper, J. Mancino, and S. Kalhan Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes Diabetes Care 27 2004 33 40 (Pubitemid 38196706)
263. S.R. Smith, N.J. Weissman, and C.M. Anderson Multicenter, placebo-controlled trial of lorcaserin for weight management N Engl J Med 363 2010 245 256
264. M.C. Fidler, M. Sanchez, and B. Raether A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial J Clin Endocrinol Metab 96 2011 3067 3077
265. P.M. O'Neil, S.R. Smith, and N.J. Weissman Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study Obesity (Silver Spring) 20 2012 1426 1436
266. H.E. Bays Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development Expert Rev Cardiovasc Ther 9 2011 265 277
267. H.E. Bays Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease Expert Rev Cardiovasc Ther 7 2009 1429 1445
268. D.B. Allison, K.M. Gadde, and W.T. Garvey Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP) Obesity (Silver Spring) 20 2012 330 342
269. K.M. Gadde, D.B. Allison, and D.H. Ryan Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial Lancet 377 2011 1341 1352
270. M.H. Davidson, S. Tonstad, S. Oparil, M. Schwiers, W.W. Day, and C.H. Bowden Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index >/=27 kg/m(2) Am J Cardiol 111 8 2013 1131 1138
271. F.L. Greenway, K. Fujioka, and R.A. Plodkowski Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet 376 2010 595 605
272. K.A. Elder, and B.M. Wolfe Bariatric surgery: a review of procedures and outcomes Gastroenterology 132 2007 2253 2271 (Pubitemid 46693754)
273. H.R. Hady, P. Golaszewski, R.L. Zbucki, and J. Dadan The influence of laparoscopic adjustable gastric banding and laparoscopic sleeve gastrectomy on weight loss, plasma ghrelin, insulin, glucose and lipids Folia Histochem Cytobiol 50 2012 292 303
274. D. Benaiges, J.A. Flores-Le-Roux, and J. Pedro-Botet Impact of restrictive (sleeve gastrectomy) vs hybrid bariatric surgery (Roux-en-Y gastric bypass) on lipid profile Obes Surg 22 2012 1268 1275
275. S.P. Donadelli, W. Salgado Jr., and J.S. Marchini Change in predicted 10-year cardiovascular risk following Roux-en-Y gastric bypass surgery: who benefits? Obes Surg 21 2011 569 573
276. Textbook of Obesity: Biological, Psychological and Cultural Influences S. Akabas, S.A. Lederman, and B. Moore 1 ed 2012 Whiley-Blackwell UK
277. F.B. Langer, M.A. Reza Hoda, and A. Bohdjalian Sleeve gastrectomy and gastric banding: effects on plasma ghrelin levels Obes Surg 15 2005 1024 1029 (Pubitemid 41116888)
278. J.A. Waitman, and L.J. Aronne Obesity surgery: pros and cons J Endocrinol Invest 25 2002 925 928 (Pubitemid 35446363)
279. K.B. Jones Jr. Experience with the Roux-en-Y gastric bypass, and commentary on current trends Obes Surg 10 2000 183 185
280. W.J. Pories, M.S. Swanson, and K.G. MacDonald Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus Ann Surg 222 1995 339 350 discussion 350-332
281. E.J. DeMaria, H.J. Sugerman, and J.G. Meador High failure rate after laparoscopic adjustable silicone gastric banding for treatment of morbid obesity Ann Surg 233 2001 809 818 (Pubitemid 32494562)
282. L. Fischer, C. Hildebrandt, and T. Bruckner Excessive weight loss after sleeve gastrectomy: a systematic review Obes Surg 22 2012 721 731
283. J.E. Varela Laparoscopic sleeve gastrectomy versus laparoscopic adjustable gastric banding for the treatment severe obesity in high risk patients JSLS 15 2011 486 491
284. L. Sjostrom Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery J Intern Med 273 2013 219 234
285. A. Iannelli, R. Anty, A.S. Schneck, A. Tran, and J. Gugenheim Inflammation, insulin resistance, lipid disturbances, anthropometrics, and metabolic syndrome in morbidly obese patients: a case control study comparing laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy Surgery 149 2011 364 370
286. L.M. Beckman, T.R. Beckman, and C.P. Earthman Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass procedure: a review J Am Diet Assoc 110 2010 571 584
287. R.E. Brolin, L.J. Bradley, A.C. Wilson, and R.P. Cody Lipid risk profile and weight stability after gastric restrictive operations for morbid obesity J Gastrointest Surg 4 2000 464 469
288. N.T. Nguyen, E. Varela, A. Sabio, C.L. Tran, M. Stamos, and S.E. Wilson Resolution of hyperlipidemia after laparoscopic Roux-en-Y gastric bypass J Am Coll Surg 203 2006 24 29
289. I. Garcia-Marirrodriga, C. Amaya-Romero, and G.P. Ruiz-Diaz Evolution of lipid profiles after bariatric surgery Obes Surg 22 2012 609 616
290. E.A. Teeple, S. Teich, D.P. Schuster, and M.P. Michalsky Early metabolic improvement following bariatric surgery in morbidly obese adolescents Pediatr Blood Cancer 58 2012 112 116
291. R.M. Dallal, A. Hatalski, A. Trang, and A. Chernoff Longitudinal analysis of cardiovascular parameters after gastric bypass surgery Surg Obes Relat Dis 8 2012 703 709
292. B.F. Asztalos, M.M. Swarbrick, and E.J. Schaefer Effects of weight loss, induced by gastric bypass surgery, on HDL remodeling in obese women J Lipid Res 51 2010 2405 2412
293. F. Illan-Gomez, M. Gonzalvez-Ortega, and I. Orea-Soler Obesity and inflammation: change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery Obes Surg 22 2012 950 955
294. G.A. Woodard, J. Peraza, S. Bravo, L. Toplosky, T. Hernandez-Boussard, and J.M. Morton One year improvements in cardiovascular risk factors: a comparative trial of laparoscopic Roux-en-Y gastric bypass vs. adjustable gastric banding Obes Surg 20 2010 578 582
295. H. Bays, and C. Ballantyne Adiposopathy: why do adiposity and obesity cause metabolic disease? Future Lipidol 1 2006 389 420
296. J.R. Seckl, N.M. Morton, K.E. Chapman, and B.R. Walker Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue Recent Prog Horm Res 59 2004 359 393
297. R. Baudrand, C.A. Carvajal, and A. Riquelme Overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in hepatic and visceral adipose tissue is associated with metabolic disorders in morbidly obese patients Obes Surg 20 2010 77 83
298. Y. Yang, H.L. Lu, and J. Zhang Relationships among acylation stimulating protein, adiponectin and complement C3 in lean vs obese type 2 diabetes Int J Obes (Lond) 30 2006 439 446
299. M. Schweiger, R. Schreiber, and G. Haemmerle Adipose triglyceride lipase and hormone-sensitive lipase are the major enzymes in adipose tissue triacylglycerol catabolism J Biol Chem 281 2006 40236 40241 (Pubitemid 46041828)
300. G.R. Steinberg, B.E. Kemp, and M.J. Watt Adipocyte triglyceride lipase expression in human obesity Am J Physiol Endocrinol Metab 293 2007 E958 E964
301. S.G. Young, and R. Zechner Biochemistry and pathophysiology of intravascular and intracellular lipolysis Genes Dev 27 2013 459 484
302. H. Bays, L. Mandarino, and R.A. DeFronzo Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach J Clin Endocrinol Metab 89 2004 463 478 (Pubitemid 38269844)
303. A. Villaret, J. Galitzky, and P. Decaunes Adipose tissue endothelial cells from obese human subjects: differences among depots in angiogenic, metabolic, and inflammatory gene expression and cellular senescence Diabetes 59 2010 2755 2763
304. O. Adeyo, C.N. Goulbourne, A. Bensadoun, A.P. Beigneux, L.G. Fong, and S.G. Young Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 and the intravascular processing of triglyceride-rich lipoproteins J Intern Med 272 2012 528 540
305. D.A. Elkins, and D.M. Spurlock Phosphorylation of perilipin is associated with indicators of lipolysis in Holstein cows Horm Metab Res 41 2009 736 740
306. J. Deng, S. Liu, L. Zou, C. Xu, B. Geng, and G. Xu Lipolysis response to endoplasmic reticulum stress in adipose cells J Biol Chem 287 2012 6240 6249
307. C. Sewter, D. Berger, and R.V. Considine Human obesity and type 2 diabetes are associated with alterations in SREBP1 isoform expression that are reproduced ex vivo by tumor necrosis factor-alpha Diabetes 51 2002 1035 1041 (Pubitemid 34438347)
308. G.J. Hausman, S.P. Poulos, and R.L. Richardson Secreted proteins and genes in fetal and neonatal pig adipose tissue and stromal-vascular cells J Anim Sci 84 2006 1666 1681 (Pubitemid 44033955)
309. X. Ruan, Z. Li, and Y. Zhang Apolipoprotein A-I possesses an anti-obesity effect associated with increase of energy expenditure and up-regulation of UCP1 in brown fat J Cell Mol Med 15 2011 763 772
310. R. Barbaras, P. Puchois, J.C. Fruchart, and G. Ailhaud Cholesterol efflux from cultured adipose cells is mediated by LpAI particles but not by LpAI: AII particles Biochem Biophys Res Commun 142 1987 63 69 (Pubitemid 17000756)
311. M. Muurling, A.M. van den Hoek, and R.P. Mensink Overexpression of APOC1 in obob mice leads to hepatic steatosis and severe hepatic insulin resistance J Lipid Res 45 2004 9 16 (Pubitemid 38176610)
312. Perdomo G DH. Apolipoprotein D in lipid metabolism and Its functional implication in atherosclerosis and aging. Aging (Albany NY). 2008;1:17-27.
313. Z.H. Huang, R.M. Luque, R.D. Kineman, and T. Mazzone Nutritional regulation of adipose tissue apolipoprotein E expression Am J Physiol Endocrinol Metab 293 2007 E203 E209
314. L. Yue, and T. Mazzone Peroxisome proliferator-activated receptor {gamma} stimulation of adipocyte ApoE gene transcription mediated by the liver receptor X pathway J Biol Chem 284 2009 10453 10461
315. C.F. Ebenbichler, M. Laimer, and S. Kaser Relationship between cholesteryl ester transfer protein and atherogenic lipoprotein profile in morbidly obese women Arterioscler Thromb Vasc Biol 22 2002 1465 1469
316. A. Yazdanyar, C. Yeang, and X.C. Jiang Role of phospholipid transfer protein in high-density lipoprotein- mediated reverse cholesterol transport Curr Atheroscler Rep 13 2011 242 248
317. S. Chung, J.K. Sawyer, A.K. Gebre, N. Maeda, and J.S. Parks Adipose tissue ATP binding cassette transporter A1 contributes to high-density lipoprotein biogenesis in vivo Circulation 124 2011 1663 1672
318. M.D. Black, G.B. Varty, and M. Arad Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat Psychopharmacology (Berl) 202 2009 385 396
319. N. Franck, K.G. Stenkula, A. Ost, T. Lindstrom, P. Stralfors, and F.H. Nystrom Insulin-induced GLUT4 translocation to the plasma membrane is blunted in large compared with small primary fat cells isolated from the same individual Diabetologia 50 2007 1716 1722 (Pubitemid 47036658)
320. G. Wolf Role of fatty acids in the development of insulin resistance and type 2 diabetes mellitus Nutr Rev 66 2008 597 600
321. J.C. Mamo, G.F. Watts, P.H. Barrett, D. Smith, A.P. James, and S. Pal Postprandial dyslipidemia in men with visceral obesity: an effect of reduced LDL receptor expression? Am J Physiol Endocrinol Metab 281 2001 E626 E632
322. W.E. Connor, and S.L. Connor Importance of diet in the treatment of familial hypercholesterolemia Am J Cardiol 72 1993 42D 53D (Pubitemid 23286502)
323. O.S. Descamps, S. Tenoutasse, and X. Stephenne Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization Atherosclerosis 218 2011 272 280
324. S. Collins, and R.S. Surwit The beta-adrenergic receptors and the control of adipose tissue metabolism and thermogenesis Recent Prog Horm Res 56 2001 309 328
325. J.E. Hall, A.A. da Silva, and J.M. do Carmo Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins J Biol Chem 285 2010 17271 17276
326. A. Bonen, N.N. Tandon, J.F. Glatz, J.J. Luiken, and G.J. Heigenhauser The fatty acid transporter FAT/CD36 is upregulated in subcutaneous and visceral adipose tissues in human obesity and type 2 diabetes Int J Obes (Lond) 30 2006 877 883 (Pubitemid 43801185)
327. L. Cai, Z. Wang, W. Ji, and J. Meyer Scavenger receptor CD36 expression contributes to adipose tissue inflammation and cell death in diet-induced obesity PLoS One 7 2012 e36785
328. L. Love-Gregory, R. Sherva, and L. Sun Variants in the CD36 gene associate with the metabolic syndrome and high-density lipoprotein cholesterol Hum Mol Genet 17 2008 1695 1704 (Pubitemid 351737173)
329. F. Laugerette, P. Passilly-Degrace, and B. Patris CD36 involvement in orosensory detection of dietary lipids, spontaneous fat preference, and digestive secretions J Clin Invest 115 2005 3177 3184 (Pubitemid 41567582)
330. A.M. Joosen, A.H. Bakker, A.H. Zorenc, S. Kersten, P. Schrauwen, and K.R. Westerterp PPARgamma activity in subcutaneous abdominal fat tissue and fat mass gain during short-term overfeeding Int J Obes (Lond) 30 2006 302 307 (Pubitemid 43237687)
331. F. Carbone, C. La Rocca, and G. Matarese Immunological functions of leptin and adiponectin Biochimie 94 2012 2082 2088
332. A. Stofkova Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity Endocr Regul 43 2009 157 168
333. F.M. Silva, J.C. de Almeida, and A.M. Feoli Effect of diet on adiponectin levels in blood Nutr Rev 69 2011 599 612
334. X. Prieur, Y.C. Tung, J.L. Griffin, I.S. Farooqi, S. O'Rahilly, and A.P. Coll Leptin regulates peripheral lipid metabolism primarily through central effects on food intake Endocrinology 149 2008 5432 5439
335. W.A. Banks, A.B. Coon, and S.M. Robinson Triglycerides induce leptin resistance at the blood-brain barrier Diabetes 53 2004 1253 1260 (Pubitemid 38569011)
336. K.A. Krawczewski Carhuatanta, G. Demuro, M.H. Tschop, P.T. Pfluger, S.C. Benoit, and S. Obici Voluntary exercise improves high-fat diet-induced leptin resistance independent of adiposity Endocrinology 152 2011 2655 2664
337. A.S. Morisset, C. Huot, D. Legare, and A. Tchernof Circulating IL-6 concentrations and abdominal adipocyte isoproterenol-stimulated lipolysis in women Obesity (Silver Spring) 16 2008 1487 1492 (Pubitemid 351915113)
338. R.M. Krauss, P.J. Blanche, R.S. Rawlings, H.S. Fernstrom, and P.T. Williams Separate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia Am J Clin Nutr 83 2006 1025 1031 quiz 1205 (Pubitemid 44713100)
339. J.S. Volek, M.J. Sharman, and A.L. Gomez Comparison of a very low-carbohydrate and low-fat diet on fasting lipids, LDL subclasses, insulin resistance, and postprandial lipemic responses in overweight women J Am Coll Nutr 23 2004 177 184 (Pubitemid 38405977)
340. Y.W. Aude, A.S. Agatston, and F. Lopez-Jimenez The national cholesterol education program diet vs a diet lower in carbohydrates and higher in protein and monounsaturated fat: a randomized trial Arch Intern Med 164 2004 2141 2146 (Pubitemid 39410804)
341. M.J. Sharman, A.L. Gomez, W.J. Kraemer, and J.S. Volek Very low-carbohydrate and low-fat diets affect fasting lipids and postprandial lipemia differently in overweight men J Nutr 134 2004 880 885 (Pubitemid 38456258)
342. M.J. Sharman, and J.S. Volek Weight loss leads to reductions in inflammatory biomarkers after a very-low-carbohydrate diet and a low-fat diet in overweight men Clin Sci (Lond) 107 2004 365 369 (Pubitemid 39389303)
343. U. Bradley, M. Spence, and C.H. Courtney Low-fat versus low-carbohydrate weight reduction diets: effects on weight loss, insulin resistance, and cardiovascular risk: a randomized control trial Diabetes 58 2009 2741 2748
344. J. Tay, G.D. Brinkworth, M. Noakes, J. Keogh, and P.M. Clifton Metabolic effects of weight loss on a very-low-carbohydrate diet compared with an isocaloric high-carbohydrate diet in abdominally obese subjects J Am Coll Cardiol 51 2008 59 67
345. F. Muzio, L. Mondazzi, W.S. Harris, D. Sommariva, and A. Branchi Effects of moderate variations in the macronutrient content of the diet on cardiovascular disease risk factors in obese patients with the metabolic syndrome Am J Clin Nutr 86 2007 946 951 (Pubitemid 47538294)
346. D.K. Layman, R.A. Boileau, and D.J. Erickson A reduced ratio of dietary carbohydrate to protein improves body composition and blood lipid profiles during weight loss in adult women J Nutr 133 2003 411 417 (Pubitemid 36172892)
347. B. Parker, M. Noakes, N. Luscombe, and P. Clifton Effect of a high-protein, high-monounsaturated fat weight loss diet on glycemic control and lipid levels in type 2 diabetes Diabetes Care 25 2002 425 430 (Pubitemid 41103331)
348. E. Farnsworth, N.D. Luscombe, M. Noakes, G. Wittert, E. Argyiou, and P.M. Clifton Effect of a high-protein, energy-restricted diet on body composition, glycemic control, and lipid concentrations in overweight and obese hyperinsulinemic men and women Am J Clin Nutr 78 2003 31 39 (Pubitemid 39655245)
349. G. Boden, K. Sargrad, C. Homko, M. Mozzoli, and T.P. Stein Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes Ann Intern Med 142 2005 403 411
350. F.F. Samaha, N. Iqbal, and P. Seshadri A low-carbohydrate as compared with a low-fat diet in severe obesity N Engl J Med 348 2003 2074 2081 (Pubitemid 36583302)
351. W.S. Yancy Jr., M. Foy, A.M. Chalecki, M.C. Vernon, and E.C. Westman A low-carbohydrate, ketogenic diet to treat type 2 diabetes Nutr Metab (Lond) 2 2005 34
352. E.C. Westman, W.S. Yancy Jr., J.C. Mavropoulos, M. Marquart, and J.R. McDuffie The effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index diet on glycemic control in type 2 diabetes mellitus Nutr Metab (Lond) 5 2008 36
353. M.E. Daly, R. Paisey, and R. Paisey Short-term effects of severe dietary carbohydrate-restriction advice in Type 2 diabetes-a randomized controlled trial Diabet Med 23 2006 15 20
354. P.A. Dyson, S. Beatty, and D.R. Matthews A low-carbohydrate diet is more effective in reducing body weight than healthy eating in both diabetic and non-diabetic subjects Diabet Med 24 2007 1430 1435 (Pubitemid 350179443)
355. B.J. Brehm, R.J. Seeley, S.R. Daniels, and D.A. D'Alessio A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular risk factors in healthy women J Clin Endocrinol Metab 88 2003 1617 1623 (Pubitemid 36623378)
356. J.S. Volek, S.D. Phinney, and C.E. Forsythe Carbohydrate restriction has a more favorable impact on the metabolic syndrome than a low fat diet Lipids 44 2009 297 309
357. B.J. Brehm, S.E. Spang, B.L. Lattin, R.J. Seeley, S.R. Daniels, and D.A. D'Alessio The role of energy expenditure in the differential weight loss in obese women on low-fat and low-carbohydrate diets J Clin Endocrinol Metab 90 2005 1475 1482 (Pubitemid 40464007)
358. W.S. Yancy Jr., M.K. Olsen, J.R. Guyton, R.P. Bakst, and E.C. Westman A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial Ann Intern Med 140 2004 769 777
359. C.S. Johnston, S.L. Tjonn, P.D. Swan, A. White, H. Hutchins, and B. Sears Ketogenic low-carbohydrate diets have no metabolic advantage over nonketogenic low-carbohydrate diets Am J Clin Nutr 83 2006 1055 1061 (Pubitemid 44713104)
360. T. McLaughlin, S. Carter, and C. Lamendola Clinical efficacy of two hypocaloric diets that vary in overweight patients with type 2 diabetes: comparison of moderate fat versus carbohydrate reductions Diabetes Care 30 2007 1877 1879 (Pubitemid 47036371)
361. T. McLaughlin, S. Carter, and C. Lamendola Effects of moderate variations in macronutrient composition on weight loss and reduction in cardiovascular disease risk in obese, insulin-resistant adults Am J Clin Nutr 84 2006 813 821 (Pubitemid 44715663)
362. Look Ahead Research Group Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial Diabetes Care 30 2007 1374 1383
363. R.R. Wing Look Ahead Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial Arch Intern Med 170 2010 1566 1575
364. N.D. Barnard, J. Cohen, and D.J. Jenkins A low-fat vegan diet and a conventional diabetes diet in the treatment of type 2 diabetes: a randomized, controlled, 74-wk clinical trial Am J Clin Nutr 89 2009 1588S 1596S
365. G.D. Brinkworth, M. Noakes, J.B. Keogh, N.D. Luscombe, G.A. Wittert, and P.M. Clifton Long-term effects of a high-protein, low-carbohydrate diet on weight control and cardiovascular risk markers in obese hyperinsulinemic subjects Int J Obes Relat Metab Disord 28 2004 661 670 (Pubitemid 38580973)
366. Y. Ma, B.C. Olendzki, and P.A. Merriam A randomized clinical trial comparing low-glycemic index versus ADA dietary education among individuals with type 2 diabetes Nutrition 24 2008 45 56 (Pubitemid 350216377)
367. C.L. Rock, S.W. Flatt, N.E. Sherwood, N. Karanja, B. Pakiz, and C.A. Thomson Effect of a free prepared meal and incentivized weight loss program on weight loss and weight loss maintenance in obese and overweight women: a randomized controlled trial JAMA 304 2010 1803 1810
368. G.D. Foster, H.R. Wyatt, and J.O. Hill Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial Ann Intern Med 153 2010 147 157
369. G.D. Brinkworth, M. Noakes, J.D. Buckley, J.B. Keogh, and P.M. Clifton Long-term effects of a very-low-carbohydrate weight loss diet compared with an isocaloric low-fat diet after 12 mo Am J Clin Nutr 90 2009 23 32
370. B.J. Brehm, B.L. Lattin, and S.S. Summer One-year comparison of a high-monounsaturated fat diet with a high-carbohydrate diet in type 2 diabetes Diabetes Care 32 2009 215 220
371. Z. Li, K. Hong, and P. Saltsman Long-term efficacy of soy-based meal replacements vs an individualized diet plan in obese type II DM patients: relative effects on weight loss, metabolic parameters, and C-reactive protein Eur J Clin Nutr 59 2005 411 418 (Pubitemid 40403296)
372. L.J. Cheskin, A.M. Mitchell, and A.D. Jhaveri Efficacy of meal replacements versus a standard food-based diet for weight loss in type 2 diabetes: a controlled clinical trial Diabetes Educ 34 2008 118 127
373. C. Richard, P. Couture, and S. Desroches Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome Br J Nutr 107 2012 705 711
374. R.E. Ratner Diabetes Prevention Program Research. An update on the Diabetes Prevention Program Endocr Pract 12 Suppl 1 2006 20 24 (Pubitemid 44963606)
375. K. Esposito, M.I. Maiorino, and M. Ciotola Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial Ann Intern Med 151 2009 306 314
376. S.H. Boutcher, and S.L. Dunn Factors that may impede the weight loss response to exercise-based interventions Obes Rev 10 2009 671 680
377. W.A. Rader, G.M. Steelman, and E.C. Westman Clinical experience using appetite suppressants and SSRIs J Okla State Med Assoc 101 2008 180 181
378. Genentech USA.Inc. Xenical Prescribing Information http://www.gene.com/ gene/products/information/xenical/pdf/pi.pdf. 2012; Accessed July 28, 2012.
379. Eisai Inc. Belviq Prescribing Information http://us.eisai.com/package- inserts/BelviqPI.pdf. 2012; Accessed July 28, 2012.
380. N. Abate, M. Chandalia, R. Di Paola, D.W. Foster, S.M. Grundy, and V. Trischitta Mechanisms of disease: Ectonucleotide pyrophosphatase phosphodiesterase 1 as a 'gatekeeper' of insulin receptors Nat Clin Pract Endocrinol Metab 2 2006 694 701 (Pubitemid 44901190)
381. Kelly TL. Visceral Fat Evaluation and Clinical Significance; 2012. Hologic, Inc. WP-00062. http://www.hologic.com/data/DXA-Visceral-Fat-Assessment. pdf. Accessed December, 2012.
382. H.E. Bays, R.H. Chapman, and S. Grandy The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys Int J Clin Pract 61 2007 737 747 (Pubitemid 46587875)
383. J.P. Despres, A. Golay, and L. Sjostrom Rimonabant in Obesity-Lipids Study G. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia N Engl J Med 353 2005 2121 2134 (Pubitemid 41653104)
384. L. Sjostrom, A.K. Lindroos, and M. Peltonen Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery N Engl J Med 351 2004 2683 2693 (Pubitemid 39665322)